1 / 7

Some examples from New Zealand

This document discusses the strategies employed to control the epidemic of group B meningococcal disease in New Zealand, particularly highlighting the introduction of a tailor-made, highly immunogenic vaccine against the New Zealand Neisseria meningitidis serogroup B strain. It examines the immune response differences among infants, children, and adults, as well as the importance of strain specificity in vaccine efficacy. Furthermore, it compares these responses with those obtained from Norwegian epidemic strains and highlights the advancements in penicillin susceptibility testing.

rio
Télécharger la présentation

Some examples from New Zealand

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Some examples from New Zealand

  2. FIGURE 2. Regional meningococcal diseaseburden in New Zealand in 2002. O’Hallahan J, Lennon D, Oster P.The strategy to control New Zealand’s epidemic of group B meningococcal disease. PIDJ 2004;23 (12 Suppl):S293-8

  3. Outer Membrane Vesicle vaccines

  4. New Zealand epidemic subtypeP1.7b,4 Norwegian epidemic subtypeP1.7,16 (MenBvac) Oster P, Lennon D, O'Hallahan J, et al. MeNZBTM: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23(17-18):2191-2196.

  5. In infants, the immune response measured as SBA is more strain-specific than in older children and adults. Vaccine strain Norwegian vaccine Holst J, Feiring B, Næss LM, Norheim G, Kristiansen P, Hoiby EA et al. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23(17-18):2202-2205.

  6. Penicillin susceptibility in Israel

  7. Penicillin MICs 1995 - 2005 CLSI (NCCLS) breakpoints introduced in 2005

More Related